{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:16:30Z","timestamp":1784085390270,"version":"3.55.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,24]]},"DOI":"10.7759\/cureus.44043","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:46:50Z","timestamp":1692892010000},"source":"Crossref","is-referenced-by-count":14,"title":["Beta-Blockers and Their Current Role in Maternal and Neonatal Health: A Narrative Review of the Literature"],"prefix":"10.7759","author":[{"given":"Andrea","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Lakkimsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameep","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ammar","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouksha","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashwat","family":"Kafley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrahmanya saketh","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima S","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Razzaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmitha","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzzam Ahmed","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability","volume":"15","author":"do Vale GT","year":"2019","unstructured":"do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of \u03b2-blockers: history, class differences and clinical applicability. Curr Hypertens Rev. 2019, 15:22-31. 10.2174\/1573402114666180918102735","journal-title":"Curr Hypertens Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1976.230.2.410","article-title":"Evidence for an intrarenal beta receptor in control of renin release","volume":"230","author":"Johnson JA","year":"1976","unstructured":"Johnson JA, Davis JO, Gotshall RW, Lohmeier TE, Davis JL, Braverman B, Tempel GE. Evidence for an intrarenal beta receptor in control of renin release. Am J Physiol. 1976, 230:410-8. 10.1152\/ajplegacy.1976.230.2.410","journal-title":"Am J Physiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/10.suppl_b.29","article-title":"A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force","volume":"10 Suppl B","author":"Kaumann AJ","year":"1989","unstructured":"Kaumann AJ, Hall JA, Murray KJ, Wells FC, Brown MJ. A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J. 1989, 10 Suppl B:29-37. 10.1093\/eurheartj\/10.suppl_b.29","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00051","article-title":"\u03921-blockers lower norepinephrine release by inhibiting presynaptic, facilitating \u03b21-adrenoceptors in normotensive and hypertensive rats","volume":"5","author":"Berg T","year":"2014","unstructured":"Berg T. \u03921-blockers lower norepinephrine release by inhibiting presynaptic, facilitating \u03b21-adrenoceptors in normotensive and hypertensive rats. Front Neurol. 2014, 5:51. 10.3389\/fneur.2014.00051","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(99)70272-1","article-title":"Molecular and genetic basis of beta2-adrenergic receptor function","volume":"104","author":"Liggett SB","year":"1999","unstructured":"Liggett SB. Molecular and genetic basis of beta2-adrenergic receptor function. J Allergy Clin Immunol. 1999, 104:S42-6. 10.1016\/s0091-6749(99)70272-1","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702605","article-title":"Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum","volume":"127","author":"Roberts SJ","year":"1999","unstructured":"Roberts SJ, Papaioannou M, Evans BA, Summers RJ. Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum. Br J Pharmacol. 1999, 127:949-61. 10.1038\/sj.bjp.0702605","journal-title":"Br J Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/103780","article-title":"Potential benefits of therapeutic use of \u03b22-adrenergic receptor agonists in neuroprotection and Parkinson's disease","volume":"2014","author":"Peterson L","year":"2014","unstructured":"Peterson L, Ismond KP, Chapman E, Flood P. Potential benefits of therapeutic use of \u03b22-adrenergic receptor agonists in neuroprotection and Parkinson's disease. J Immunol Res. 2014, 2014:103780. 10.1155\/2014\/103780","journal-title":"J Immunol Res"},{"key":"ref8","article-title":"Structure and function of beta3-adrenergic receptors","volume":"40","author":"Skeberdis VA","year":"2004","unstructured":"Skeberdis VA. Structure and function of beta3-adrenergic receptors. Medicina (Kaunas). 2004, 40:407-13.","journal-title":"Medicina (Kaunas)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2004.04.004","article-title":"Cardiovascular drug class specificity: beta-blockers","volume":"47","author":"Reiter MJ","year":"2004","unstructured":"Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004, 47:11-33. 10.1016\/j.pcad.2004.04.004","journal-title":"Prog Cardiovasc Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/ac.65.5.2056244","article-title":"Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why?","volume":"65","author":"Gorre F","year":"2010","unstructured":"Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why?. Acta Cardiol. 2010, 65:565-70. 10.1080\/ac.65.5.2056244","journal-title":"Acta Cardiol"},{"key":"ref11","article-title":"Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure","volume":"15","author":"Rehsia NS","year":"2010","unstructured":"Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol. 2010, 15:e86-95.","journal-title":"Exp Clin Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2010.01015.x","article-title":"\u03b2-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure","volume":"15","author":"Machackova J","year":"2011","unstructured":"Machackova J, Sanganalmath SK, Elimban V, Dhalla NS. \u03b2-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure. J Cell Mol Med. 2011, 15:545-54. 10.1111\/j.1582-4934.2010.01015.x","journal-title":"J Cell Mol Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity","volume":"31","author":"Ladage D","year":"2013","unstructured":"Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013, 31:76-83. 10.1111\/j.1755-5922.2011.00306.x","journal-title":"Cardiovasc Ther"},{"key":"ref14","article-title":"Beta Blockers","author":"Farzam K","year":"2023","unstructured":"Farzam K, Jan A. Beta Blockers. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref15","article-title":"Adrenoceptor blockers. in: Katzung & Trevor\u2019s pharmacology: examination & board review","author":"Katzung BG","year":"2021","unstructured":"Katzung BG, Kruidering-Hall M, Tuan RL, Vanderah TW, Trevor AJ. Adrenoceptor blockers. in: Katzung & Trevor\u2019s pharmacology: examination & board review. Katzung & Trevor's Pharmacology: Examination & Board Review, 13e. Katzung BG, Kruidering-Hall M, Tuan RL, Vanderah TW, Trevor AJ (ed): McGraw Hill, New York; 2021."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"L\u00f3pez-Send\u00f3n J","year":"2004","unstructured":"L\u00f3pez-Send\u00f3n J, Swedberg K, McMurray J, et al.. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004, 25:1341-62. 10.1016\/j.ehj.2004.06.002","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"Steenen SA","year":"2016","unstructured":"Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016, 30:128-39. 10.1177\/0269881115612236","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.10.1539","article-title":"Nebivolol: third-generation beta-blockade","volume":"8","author":"de Boer RA","year":"2007","unstructured":"de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007, 8:1539-50. 10.1517\/14656566.8.10.1539","journal-title":"Expert Opin Pharmacother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.17-525","article-title":"Regular treatment strategy with a large amount of carvedilol for heart failure improves biventricular systolic failure in a patient with repaired tetralogy of Fallot","volume":"59","author":"Soma K","year":"2018","unstructured":"Soma K, Yao A, Saito A, Inaba T, Ishikawa Y, Hirata Y, Komuro I. Regular treatment strategy with a large amount of carvedilol for heart failure improves biventricular systolic failure in a patient with repaired tetralogy of Fallot. Int Heart J. 2018, 59:1169-73. 10.1536\/ihj.17-525","journal-title":"Int Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","volume":"1","author":"Wiysonge CS","year":"2017","unstructured":"Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017, 1:CD002003. 10.1002\/14651858.CD002003.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccep.2018.11.001","article-title":"The many faces of heart failure","volume":"11","author":"Snipelisky D","year":"2019","unstructured":"Snipelisky D, Chaudhry SP, Stewart GC. The many faces of heart failure. Card Electrophysiol Clin. 2019, 11:11-20. 10.1016\/j.ccep.2018.11.001","journal-title":"Card Electrophysiol Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104274","article-title":"Antiarrhythmic mechanisms of beta blocker therapy","volume":"146","author":"Grandi E","year":"2019","unstructured":"Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019, 146:104274. 10.1016\/j.phrs.2019.104274","journal-title":"Pharmacol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis F","year":"2009","unstructured":"Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009, 54:1747-62. 10.1016\/j.jacc.2009.05.015","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00183.2004","article-title":"Cardiac neuronal hierarchy in health and disease","volume":"287","author":"Armour JA","year":"2004","unstructured":"Armour JA. Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol. 2004, 287:R262-71. 10.1152\/ajpregu.00183.2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(93)90030-h","article-title":"Beta-adrenoceptors in cardiac disease","volume":"60","author":"Brodde OE","year":"1993","unstructured":"Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993, 60:405-30. 10.1016\/0163-7258(93)90030-h","journal-title":"Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207223070401","article-title":"Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts","volume":"307","author":"Bristow MR","year":"1982","unstructured":"Bristow MR, Ginsburg R, Minobe W, et al.. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982, 307:205-11. 10.1056\/NEJM198207223070401","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.59.3.297","article-title":"Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure","volume":"59","author":"Bristow MR","year":"1986","unstructured":"Bristow MR, Ginsburg R, Umans V, et al.. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986, 59:297-309. 10.1161\/01.res.59.3.297","journal-title":"Circ Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee J","year":"2017","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017, 14:30-8. 10.1038\/nrcardio.2016.163","journal-title":"Nat Rev Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000487936","article-title":"Treatment of angina: where are we?","volume":"140","author":"Balla C","year":"2018","unstructured":"Balla C, Pavasini R, Ferrari R. Treatment of angina: where are we?. Cardiology. 2018, 140:52-67. 10.1159\/000487936","journal-title":"Cardiology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.037283","article-title":"Mechanisms of coronary artery spasm","volume":"124","author":"Lanza GA","year":"2011","unstructured":"Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011, 124:1774-82. 10.1161\/CIRCULATIONAHA.111.037283","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2012.184","article-title":"Revising common beliefs in the management of stable CAD","volume":"10","author":"Ferrari R","year":"2013","unstructured":"Ferrari R. Revising common beliefs in the management of stable CAD. Nat Rev Cardiol. 2013, 10:65-6. 10.1038\/nrcardio.2012.184","journal-title":"Nat Rev Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January CT","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al.. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014, 130:2071-104. 10.1161\/CIR.0000000000000040","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner TJ","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020, 21:137. 10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2021.102208","article-title":"Migraine review for general practice","volume":"54","author":"Aguilar-Shea AL","year":"2022","unstructured":"Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022, 54:102208. 10.1016\/j.aprim.2021.102208","journal-title":"Aten Primaria"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo S","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016, 388:906-18. 10.1016\/S0140-6736(16)00278-6","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.586795","article-title":"Preoperative management of pheochromocytoma and paraganglioma","volume":"11","author":"Fang F","year":"2020","unstructured":"Fang F, Ding L, He Q, Liu M. Preoperative management of pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2020, 11:586795. 10.3389\/fendo.2020.586795","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders JW","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, et al.. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014, 99:1915-42. 10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198203183061102","article-title":"Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?","volume":"306","author":"Taylor SH","year":"1982","unstructured":"Taylor SH, Silke B, Lee PS. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?. N Engl J Med. 1982, 306:631-5. 10.1056\/NEJM198203183061102","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials","volume":"164","author":"Ko DT","year":"2004","unstructured":"Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004, 164:1389-94. 10.1001\/archinte.164.13.1389","journal-title":"Arch Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198304213081606","article-title":"Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity","volume":"308","author":"Frishman WH","year":"1983","unstructured":"Frishman WH. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983, 308:940-4. 10.1056\/NEJM198304213081606","journal-title":"N Engl J Med"},{"key":"ref41","article-title":"Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice","volume":"4","author":"Ormiston TM","year":"2003","unstructured":"Ormiston TM, Salpeter SR. Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail Monit. 2003, 4:45-54.","journal-title":"Heart Fail Monit"},{"key":"ref42","article-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk: Tenth Edition","author":"Briggs GG","year":"2015","unstructured":"Briggs GG, Freeman RK. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk: Tenth Edition.  Lippincott Williams & Wilkins (LWW), Philadelphia, PA; 2015."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000162867","article-title":"The effect of propranolol upon chick embryo cardiogenesis","volume":"45","author":"Gilani SH","year":"1977","unstructured":"Gilani SH, Silvestri A. The effect of propranolol upon chick embryo cardiogenesis. Exp Cell Biol. 1977, 45:158-66. 10.1159\/000162867","journal-title":"Exp Cell Biol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00833","article-title":"The risk of congenital malformations associated with exposure to \u03b2-blockers early in pregnancy: a meta-analysis","volume":"62","author":"Yakoob MY","year":"2013","unstructured":"Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin JM, Goodman JE, Hoban RA. The risk of congenital malformations associated with exposure to \u03b2-blockers early in pregnancy: a meta-analysis. Hypertension. 2013, 62:375-81. 10.1161\/HYPERTENSIONAHA.111.00833","journal-title":"Hypertension"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0338","article-title":"\u0392-blocker use in pregnancy and the risk for congenital malformations: an international cohort study","volume":"169","author":"Bateman BT","year":"2018","unstructured":"Bateman BT, Heide-J\u00f8rgensen U, Einarsd\u00f3ttir K, et al.. \u0392-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018, 169:665-73. 10.7326\/M18-0338","journal-title":"Ann Intern Med"},{"key":"ref46","unstructured":"Propranolol. medicine for heart problems, anxiety and migraine. (2021). Accessed: June 19th, 2023: https:\/\/www.nhs.uk\/medicines\/propranolol\/.."},{"key":"ref47","unstructured":"Beta blockers, systemic. (2023). Accessed. June 19, 2023: https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/groepsteksten\/betablokkers__systemisch."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1515\/prilozi-2017-0013","article-title":"Neonatal hypoglycemia: risk factors and outcomes","volume":"38","author":"Stomnaroska O","year":"2017","unstructured":"Stomnaroska O, Petkovska E, Jancevska S, Danilovski D. Neonatal hypoglycemia: risk factors and outcomes. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017, 38:97-101. 10.1515\/prilozi-2017-0013","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2822","article-title":"Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia","volume":"122","author":"Burns CM","year":"2008","unstructured":"Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics. 2008, 122:65-74. 10.1542\/peds.2007-2822","journal-title":"Pediatrics"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055292","article-title":"Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol","volume":"12","author":"de Bruin R","year":"2022","unstructured":"de Bruin R, van Dalen SL, Franx SJ, Simons SH, Flint RB, van den Bosch GE. Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol. BMJ Open. 2022, 12:e055292. 10.1136\/bmjopen-2021-055292","journal-title":"BMJ Open"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2016-021","article-title":"Physiological changes in pregnancy","volume":"27","author":"Soma-Pillay P","year":"2016","unstructured":"Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016, 27:89-94. 10.5830\/CVJA-2016-021","journal-title":"Cardiovasc J Afr"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308476","article-title":"Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses","volume":"102","author":"Meah VL","year":"2016","unstructured":"Meah VL, Cockcroft JR, Backx K, Shave R, St\u00f6hr EJ. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. Heart. 2016, 102:518-26. 10.1136\/heartjnl-2015-308476","journal-title":"Heart"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.07.009","article-title":"The heart during pregnancy [Article in Spanish]","volume":"64","author":"Hall ME","year":"2011","unstructured":"Hall ME, George EM, Granger JP. The heart during pregnancy [Article in Spanish]. Rev Esp Cardiol. 2011, 64:1045-50. 10.1016\/j.recesp.2011.07.009","journal-title":"Rev Esp Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.05.048","article-title":"High-risk cardiac disease in pregnancy: part I","volume":"68","author":"Elkayam U","year":"2016","unstructured":"Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy: part I. J Am Coll Cardiol. 2016, 68:396-410. 10.1016\/j.jacc.2016.05.048","journal-title":"J Am Coll Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06667","article-title":"Maternal cardiovascular function in normal pregnancy: evidence of maladaptation to chronic volume overload","volume":"67","author":"Melchiorre K","year":"2016","unstructured":"Melchiorre K, Sharma R, Khalil A, Thilaganathan B. Maternal cardiovascular function in normal pregnancy: evidence of maladaptation to chronic volume overload. Hypertension. 2016, 67:754-62. 10.1161\/HYPERTENSIONAHA.115.06667","journal-title":"Hypertension"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197748","article-title":"Maternal cardiovascular and endothelial function from first trimester to postpartum","volume":"13","author":"Kolovetsiou-Kreiner V","year":"2018","unstructured":"Kolovetsiou-Kreiner V, Moertl MG, Papousek I, et al.. Maternal cardiovascular and endothelial function from first trimester to postpartum. PLoS One. 2018, 13:e0197748. 10.1371\/journal.pone.0197748","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000090","article-title":"A longitudinal study of maternal cardiovascular function from preconception to the postpartum period","volume":"32","author":"Mahendru AA","year":"2014","unstructured":"Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014, 32:849-56. 10.1097\/HJH.0000000000000090","journal-title":"J Hypertens"},{"key":"ref58","article-title":"Incidence of pregnancy induced hypertension and prescription pattern of antihypertensive drugs in pregnancy","volume":"5","author":"Sajith M","year":"2014","unstructured":"Sajith M, Nimbargi V, Modi A, Sumariya R, Pawar A. Incidence of pregnancy induced hypertension and prescription pattern of antihypertensive drugs in pregnancy. Int J Pharm Sci Res. 2014, 5:163-70.","journal-title":"Int J Pharm Sci Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119843700","article-title":"Hypertension in pregnancy: pathophysiology and treatment","volume":"7","author":"Braunthal S","year":"2019","unstructured":"Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019, 7:2050312119843700. 10.1177\/2050312119843700","journal-title":"SAGE Open Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13649","article-title":"Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"84","author":"Sridharan K","year":"2018","unstructured":"Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018, 84:1906-16. 10.1111\/bcp.13649","journal-title":"Br J Clin Pharmacol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03382-3","article-title":"Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review","volume":"78","author":"van de Vusse D","year":"2022","unstructured":"van de Vusse D, Mian P, Schoenmakers S, Flint RB, Visser W, Allegaert K, Versmissen J. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. Eur J Clin Pharmacol. 2022, 78:1763-76. 10.1007\/s00228-022-03382-3","journal-title":"Eur J Clin Pharmacol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.2002845","article-title":"The impact of pregnancy on antihypertensive drug metabolism and pharmacokinetics: current status and future directions","volume":"17","author":"Mulrenin IR","year":"2021","unstructured":"Mulrenin IR, Garcia JE, Fashe MM, Loop MS, Daubert MA, Urrutia RP, Lee CR. The impact of pregnancy on antihypertensive drug metabolism and pharmacokinetics: current status and future directions. Expert Opin Drug Metab Toxicol. 2021, 17:1261-79. 10.1080\/17425255.2021.2002845","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0123-0","article-title":"Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy","volume":"53","author":"Fischer JH","year":"2014","unstructured":"Fischer JH, Sarto GE, Hardman J, et al.. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet. 2014, 53:373-83. 10.1007\/s40262-013-0123-0","journal-title":"Clin Pharmacokinet"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13397","article-title":"Beta-blocker subtypes and risk of low birth weight in newborns","volume":"20","author":"Duan L","year":"2018","unstructured":"Duan L, Ng A, Chen W, Spencer HT, Lee MS. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich). 2018, 20:1603-9. 10.1111\/jch.13397","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0617","article-title":"Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease","volume":"80","author":"Tanaka K","year":"2016","unstructured":"Tanaka K, Tanaka H, Kamiya C, et al.. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016, 80:2221-6. 10.1253\/circj.CJ-15-0617","journal-title":"Circ J"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001185","article-title":"\u03b2-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study","volume":"2","author":"Meidahl Petersen K","year":"2012","unstructured":"Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al.. \u03b2-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012, 2:e001185. 10.1136\/bmjopen-2012-001185","journal-title":"BMJ Open"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.0608","article-title":"\u0392-blocker exposure in pregnancy and risk of fetal cardiac anomalies","volume":"177","author":"Duan L","year":"2017","unstructured":"Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY, Lee MS. \u0392-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med. 2017, 177:885-7. 10.1001\/jamainternmed.2017.0608","journal-title":"JAMA Intern Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14363","article-title":"Maternal beta-blocker dose and risk of small-for gestational-age in women with heart disease","volume":"101","author":"S\u00f8rbye IK","year":"2022","unstructured":"S\u00f8rbye IK, Haualand R, Wiull H, Letting AS, Langesaeter E, Estensen ME. Maternal beta-blocker dose and risk of small-for gestational-age in women with heart disease. Acta Obstet Gynecol Scand. 2022, 101:794-802. 10.1111\/aogs.14363","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1235","article-title":"Adverse respiratory effect of acute \u03b2-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Morales DR","year":"2014","unstructured":"Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute \u03b2-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014, 145:779-86. 10.1378\/chest.13-1235","journal-title":"Chest"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02483-1","article-title":"Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study","volume":"20","author":"Ardissino M","year":"2022","unstructured":"Ardissino M, Slob EA, Rajasundaram S, et al.. Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study. BMC Med. 2022, 20:288. 10.1186\/s12916-022-02483-1","journal-title":"BMC Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-22-0647","article-title":"\u0391\/\u03b2- and \u03b2-blocker exposure in pregnancy and the risk of neonatal hypoglycemia and small for gestational age","volume":"87","author":"Kubota K","year":"2023","unstructured":"Kubota K, Inai K, Shimada E, Shinohara T. \u0391\/\u03b2- and \u03b2-blocker exposure in pregnancy and the risk of neonatal hypoglycemia and small for gestational age. Circ J. 2023, 87:569-77. 10.1253\/circj.CJ-22-0647","journal-title":"Circ J"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.013","article-title":"Cardiac medication during pregnancy, data from the ROPAC","volume":"177","author":"Ruys TP","year":"2014","unstructured":"Ruys TP, Maggioni A, Johnson MR, et al.. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 2014, 177:124-8. 10.1016\/j.ijcard.2014.09.013","journal-title":"Int J Cardiol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1242\/bio.058999","article-title":"Investigating the effect of cholinergic and adrenergic blocking agents on maternal-fetal heart rates and their interactions in mice fetuses","volume":"11","author":"Khandoker AH","year":"2022","unstructured":"Khandoker AH, Wahbah M, Yoshida C, Kasahara Y, Funamoto K, Niizeki K, Kimura Y. Investigating the effect of cholinergic and adrenergic blocking agents on maternal-fetal heart rates and their interactions in mice fetuses. Biol Open. 2022, 11:bio058999. 10.1242\/bio.058999","journal-title":"Biol Open"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0731","article-title":"Late pregnancy \u03b2 blocker exposure and risks of neonatal hypoglycemia and bradycardia","volume":"138","author":"Bateman BT","year":"2016","unstructured":"Bateman BT, Patorno E, Desai RJ, et al.. Late pregnancy \u03b2 blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016, 138:e20160731. 10.1542\/peds.2016-0731","journal-title":"Pediatrics"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12737","article-title":"Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review","volume":"121","author":"Firoz T","year":"2014","unstructured":"Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, von Dadelszen P. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014, 121:1210-8; discussion 1220. 10.1111\/1471-0528.12737","journal-title":"BJOG"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2019-0402","article-title":"Drug exposure during pregnancy and fetal cardiac function - a systematic review","volume":"48","author":"Kolding L","year":"2020","unstructured":"Kolding L, Eken H, Uldbjerg N. Drug exposure during pregnancy and fetal cardiac function - a systematic review. J Perinat Med. 2020, 48:199-208. 10.1515\/jpm-2019-0402","journal-title":"J Perinat Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2019-061","article-title":"The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study","volume":"31","author":"Baard J","year":"2020","unstructured":"Baard J, Azibani F, Osman A, Dowling W, Rayner B, Sliwa K. The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr. 2020, 31:136-41. 10.5830\/CVJA-2019-061","journal-title":"Cardiovasc J Afr"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2014.01.019","article-title":"Association between labetalol use for hypertension in pregnancy and adverse infant outcomes","volume":"175","author":"Xie RH","year":"2014","unstructured":"Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 2014, 175:124-8. 10.1016\/j.ejogrb.2014.01.019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-015-1250-1","article-title":"Intrauterine treatment of a fetus with familial hypertrophic cardiomyopathy secondary to MYH7 mutation","volume":"36","author":"Hill MG","year":"2015","unstructured":"Hill MG, Sekhon MK, Reed KL, Anderson CF, Borjon ND, Tardiff JC, Barber BJ. Intrauterine treatment of a fetus with familial hypertrophic cardiomyopathy secondary to MYH7 mutation. Pediatr Cardiol. 2015, 36:1774-7. 10.1007\/s00246-015-1250-1","journal-title":"Pediatr Cardiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2020.07.006","article-title":"Successful trans-maternal nadolol pharmacotherapy in a fetus presenting with long QT syndrome type 2 complicated by torsade de pointes","volume":"22","author":"Shima Y","year":"2020","unstructured":"Shima Y, Horigome H, Nozaki Y, et al.. Successful trans-maternal nadolol pharmacotherapy in a fetus presenting with long QT syndrome type 2 complicated by torsade de pointes. J Cardiol Cases. 2020, 22:265-8. 10.1016\/j.jccase.2020.07.006","journal-title":"J Cardiol Cases"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1159\/000516845","article-title":"Intrauterine growth retardation in pregnant women with long QT syndrome treated with beta-receptor blockers","volume":"118","author":"Welzel T","year":"2021","unstructured":"Welzel T, Donner B, van den Anker JN. Intrauterine growth retardation in pregnant women with long QT syndrome treated with beta-receptor blockers. Neonatology. 2021, 118:406-15. 10.1159\/000516845","journal-title":"Neonatology"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153384","article-title":"Pre-clinical investigation of cardioprotective beta-blockers as a therapeutic strategy for preeclampsia","volume":"10","author":"Binder NK","year":"2021","unstructured":"Binder NK, MacDonald TM, Beard SA, de Alwis N, Tong S, Kaitu'u-Lino TJ, Hannan NJ. Pre-clinical investigation of cardioprotective beta-blockers as a therapeutic strategy for preeclampsia. J Clin Med. 2021, 10:3384. 10.3390\/jcm10153384","journal-title":"J Clin Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2018.21.2","article-title":"Postpartum cardiomyopathy and considerations for breastfeeding","volume":"4","author":"Kearney L","year":"2018","unstructured":"Kearney L, Wright P, Fhadil S, Thomas M. Postpartum cardiomyopathy and considerations for breastfeeding. Card Fail Rev. 2018, 4:112-8. 10.15420\/cfr.2018.21.2","journal-title":"Card Fail Rev"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3641","article-title":"Prescription of antihypertensive medications during pregnancy in the UK","volume":"23","author":"Cea Soriano L","year":"2014","unstructured":"Cea Soriano L, Bateman BT, Garc\u00eda Rodr\u00edguez LA, Hern\u00e1ndez-D\u00edaz S. Prescription of antihypertensive medications during pregnancy in the UK. Pharmacoepidemiol Drug Saf. 2014, 23:1051-8. 10.1002\/pds.3641","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1177\/0890334418771308","article-title":"Estimation of atenolol transfer into milk and infant exposure during its use in lactating women","volume":"34","author":"Lwin EM","year":"2018","unstructured":"Lwin EM, Gerber C, Leggett C, et al.. Estimation of atenolol transfer into milk and infant exposure during its use in lactating women. J Hum Lact. 2018, 34:592-9. 10.1177\/0890334418771308","journal-title":"J Hum Lact"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2020008","article-title":"Oral propranolol for the treatment of infantile haemangiomas in Singapore","volume":"62","author":"Tan JM","year":"2021","unstructured":"Tan JM, Lim HW, Koh MJ. Oral propranolol for the treatment of infantile haemangiomas in Singapore. Singapore Med J. 2021, 62:139-42. 10.11622\/smedj.2020008","journal-title":"Singapore Med J"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00409-4","article-title":"Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial","volume":"22","author":"Lanfranconi S","year":"2023","unstructured":"Lanfranconi S, Scola E, Meessen JM, et al.. Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol. 2023, 22:35-44. 10.1016\/S1474-4422(22)00409-4","journal-title":"Lancet Neurol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01534-3","article-title":"Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials","volume":"400","author":"Pitcher A","year":"2022","unstructured":"Pitcher A, Spata E, Emberson J, et al.. Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022, 400:822-31. 10.1016\/S0140-6736(22)01534-3","journal-title":"Lancet"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: their new life from hypertension to cancer and migraine","volume":"151","author":"Fumagalli C","year":"2020","unstructured":"Fumagalli C, Maurizi N, Marchionni N, Fornasari D. \u03b2-blockers: their new life from hypertension to cancer and migraine. Pharmacol Res. 2020, 151:104587. 10.1016\/j.phrs.2019.104587","journal-title":"Pharmacol Res"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2009.00140.x","article-title":"Realities of newer beta-blockers for the management of hypertension","volume":"11","author":"Manrique C","year":"2009","unstructured":"Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich). 2009, 11:369-75. 10.1111\/j.1751-7176.2009.00140.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2021.10.004","article-title":"Arrhythmias in pregnancy","volume":"8","author":"Tamirisa KP","year":"2022","unstructured":"Tamirisa KP, Elkayam U, Briller JE, et al.. Arrhythmias in pregnancy. JACC Clin Electrophysiol. 2022, 8:120-35. 10.1016\/j.jacep.2021.10.004","journal-title":"JACC Clin Electrophysiol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.08.006","article-title":"Review of topical beta blockers as treatment for infantile hemangiomas","volume":"61","author":"Painter SL","year":"2016","unstructured":"Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol. 2016, 61:51-8. 10.1016\/j.survophthal.2015.08.006","journal-title":"Surv Ophthalmol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.2217\/phe.09.65","article-title":"Role of \u03b2-blocker therapy in pediatric heart failure","volume":"4","author":"Patel AR","year":"2010","unstructured":"Patel AR, Shaddy RE. Role of \u03b2-blocker therapy in pediatric heart failure. Ped Health. 2010, 4:45-58. 10.2217\/phe.09.65","journal-title":"Ped Health"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204120-00001","article-title":"Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?","volume":"4","author":"Bruns LA","year":"2002","unstructured":"Bruns LA, Canter CE. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. Paediatr Drugs. 2002, 4:771-8. 10.2165\/00128072-200204120-00001","journal-title":"Paediatr Drugs"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200810020-00007","article-title":"Pediatric heart failure therapy with beta-adrenoceptor antagonists","volume":"10","author":"Foerster SR","year":"2008","unstructured":"Foerster SR, Canter CE. Pediatric heart failure therapy with beta-adrenoceptor antagonists. Paediatr Drugs. 2008, 10:125-34. 10.2165\/00148581-200810020-00007","journal-title":"Paediatr Drugs"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.8.883","article-title":"Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial","volume":"29","author":"Zebrack JS","year":"2009","unstructured":"Zebrack JS, Munger M, Macgregor J, Lombardi WL, Stoddard GP, Gilbert EM. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. Pharmacotherapy. 2009, 29:883-90. 10.1592\/phco.29.8.883","journal-title":"Pharmacotherapy"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363160-00006","article-title":"Carvedilol: a review of its use in chronic heart failure","volume":"63","author":"Keating GM","year":"2003","unstructured":"Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003, 63:1697-741. 10.2165\/00003495-200363160-00006","journal-title":"Drugs"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6793-3-6","article-title":"Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure","volume":"3","author":"Okafor CC","year":"2003","unstructured":"Okafor CC, Perreault-Micale C, Hajjar RJ, et al.. Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiol. 2003, 3:6. 10.1186\/1472-6793-3-6","journal-title":"BMC Physiol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-200405000-00010","article-title":"The update on the rationale, use and selection of beta-blockers in heart failure","volume":"19","author":"Giesler G","year":"2004","unstructured":"Giesler G, Lenihan DJ, Durand JB. The update on the rationale, use and selection of beta-blockers in heart failure. Curr Opin Cardiol. 2004, 19:250-3. 10.1097\/00001573-200405000-00010","journal-title":"Curr Opin Cardiol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000016050.79810.18","article-title":"Bucindolol displays intrinsic sympathomimetic activity in human myocardium","volume":"105","author":"Andreka P","year":"2002","unstructured":"Andreka P, Aiyar N, Olson LC, et al.. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002, 105:2429-34. 10.1161\/01.cir.0000016050.79810.18","journal-title":"Circulation"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Eichhorn EJ","year":"2001","unstructured":"Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001, 344:1659-67. 10.1056\/NEJM200105313442202","journal-title":"N Engl J Med"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson PA","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, et al.. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362:7-13. 10.1016\/S0140-6736(03)13800-7","journal-title":"Lancet"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14015","article-title":"Trends in the off-label use of \u03b2-blockers in pediatric patients","volume":"61","author":"Kaley VR","year":"2019","unstructured":"Kaley VR, Aregullin EO, Samuel BP, Vettukattil JJ. Trends in the off-label use of \u03b2-blockers in pediatric patients. Pediatr Int. 2019, 61:1071-80. 10.1111\/ped.14015","journal-title":"Pediatr Int"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v6.i5.234","article-title":"Anti-hypertensive drugs in children and adolescents","volume":"6","author":"Chu PY","year":"2014","unstructured":"Chu PY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents. World J Cardiol. 2014, 6:234-44. 10.4330\/wjc.v6.i5.234","journal-title":"World J Cardiol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016597","article-title":"Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial","volume":"7","author":"Miyoshi T","year":"2017","unstructured":"Miyoshi T, Maeno Y, Sago H, et al.. Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial. BMJ Open. 2017, 7:e016597. 10.1136\/bmjopen-2017-016597","journal-title":"BMJ Open"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.2196\/36771","article-title":"Using Twitter data for cohort studies of drug safety in pregnancy: proof-of-concept with \u03b2-blockers","volume":"6","author":"Klein AZ","year":"2022","unstructured":"Klein AZ, O'Connor K, Levine LD, Gonzalez-Hernandez G. Using Twitter data for cohort studies of drug safety in pregnancy: proof-of-concept with \u03b2-blockers. JMIR Form Res. 2022, 6:e36771. 10.2196\/36771","journal-title":"JMIR Form Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172399-beta-blockers-and-their-current-role-in-maternal-and-neonatal-health-a-narrative-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:29Z","timestamp":1707508649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172399-beta-blockers-and-their-current-role-in-maternal-and-neonatal-health-a-narrative-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":106,"URL":"https:\/\/doi.org\/10.7759\/cureus.44043","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}